Buprenorphine HCl
53152-21-9
General information
Buprenorphine HCl is the hydrochloride salt form of buprenorphine, which belongs to the class of organic compounds known as morphinans. Buprenorphine is indicated for the treatment of opioid dependence, moderate to severe pain and peri-operative analgesia. It prevents symptoms of withdrawal from opiates such as heroin and is preferred for the induction phase of treatment (conducted under medical supervision). It is considered to be better tolerated without naloxone during the first days of treatment. Following induction, buprenorphine and naloxone are preferred due to the presence of naloxone which impedes intravenous abuse of the product. Buprenorphine HCl can be administered intravenously, as a sublingual tablet, sublingual film or subdermal implant.
Trade names
Suboxone, Buprenex, Subutex, Zubsolv, Bunavail, Temgesic, Bupensan, Bunalict
About the API
Therapeutic areas
Analgesic, opioid addiction
Available grades
Various milled & micronized
Monographs
USP, Ph. Eur.
Regulatory documentation
CEP / USDMF / CAN ASMF
DEA schedule
IIIN
Production location
Zofingen, Pennsville, Minden
Standard pack size
1kg, 5kg, 25kg
Physical properties
White or almost white crystalline powder
Typical formulation types
Oral Solid, injectable